SutroVax Secures $22,000,000 Series A Financing Round

  • Feed Type
  • Date
    7/24/2015
  • Company Name
    SutroVax
  • Mailing Address
    400 E Jamie Court South San Francisco, CA 94080 USA
  • Company Description
    SutroVax is an independent vaccine platform and development company that was spun-out of Sutro Biopharma. The company will leverage Sutro’s Xpress CF and Xpress CF+ platforms for cell-free protein synthesis and site-specific conjugation to develop novel vaccines for an array of disease targets.
  • Website
    http://www.sutrovax.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $22,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    SutroVax will use the funds to advance multiple vaccines in its pipeline through pre-clinical proof of concept.
  • M&A Terms
  • Venture Investor
    Abingworth Management
  • Venture Investor
    Longitude Capital Management
  • Venture Investor
    Roche Venture Fund
  • Venture Investor
    CTI Life Sciences Fund